• Janux Therapeutics Inc JANX.OQ reported a quarterly adjusted loss of 39 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -36 cents. The mean expectation of seventeen analysts for the quarter was for a loss of 64 cents per share. Wall Street expected results to range from $-1.02 to -46 cents per share.

• Reported revenue was zero​; analysts expected $2.93 million.

• Janux Therapeutics Inc's reported EPS for the quarter was a loss of 39 cents​.

• The company reported a quarterly loss of $41.4 million.

• Janux Therapeutics Inc shares had fallen by 0.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.3% in the last three months.​

• In the last 30 days, five analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Janux Therapeutics Inc is $53.50, about 74.4% above its last closing price of $13.70

This summary was machine generated from LSEG data February 26 at 09:26 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)